Who are Thienopyridine (open-label)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Prasugrel loading, ASA plus Clopidogrel, Aspirin and Clopidogrel, rivaroxaban and ticagrel therapy, CYP2C19 Genotype Guided DAPT, extended postimplantation dual antiplatelet therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/thienopyridine-open-label.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Thienopyridine (open-label) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thienopyridine (open-label) (Thienopyridine (open-label)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist / Antiplatelet agent. Area: Cardiovascular.

marketed P2Y12 receptor antagonist / Antiplatelet agent P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Thienopyridine (open-label) (Thienopyridine (open-label)) — VA Office of Research and Development. Thienopyridines inhibit platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Thienopyridine (open-label) TARGET	Thienopyridine (open-label)	VA Office of Research and Development	marketed	P2Y12 receptor antagonist / Antiplatelet agent	P2Y12 receptor
Prasugrel loading	Prasugrel loading	Azienda Policlinico Umberto I	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor
ASA plus Clopidogrel	ASA plus Clopidogrel	Texas Cardiac Arrhythmia Research Foundation	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel)
Aspirin and Clopidogrel	Aspirin and Clopidogrel	Assistance Publique - Hôpitaux de Paris	marketed	Antiplatelet agent (dual therapy)	Cyclooxygenase (COX) and P2Y12 receptor
rivaroxaban and ticagrel therapy	rivaroxaban and ticagrel therapy	Beijing Anzhen Hospital	marketed	Anticoagulant and antiplatelet combination therapy	Factor Xa (rivaroxaban); P2Y12 receptor (ticagrelor)
CYP2C19 Genotype Guided DAPT	CYP2C19 Genotype Guided DAPT	Zunyi Medical College	marketed	Pharmacogenomic-guided antiplatelet therapy strategy	CYP2C19 enzyme; P2Y12 receptor (indirect)
extended postimplantation dual antiplatelet therapy	extended postimplantation dual antiplatelet therapy	National Institute of Cardiology, Warsaw, Poland	marketed	Antiplatelet therapy combination	Platelet aggregation pathways (cyclooxygenase and P2Y12 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist / Antiplatelet agent class)

Centre hospitalier de l'Université de Montréal (CHUM) · 1 drug in this class
Jeil Pharmaceutical Co., Ltd. · 1 drug in this class
University of Florida · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Thienopyridine (open-label) — Competitive Intelligence Brief. https://druglandscape.com/ci/thienopyridine-open-label. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing